Portal de Periódicos da CAPES

Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation

2005; Springer Science+Business Media; Volume: 7; Issue: 3 Linguagem: Inglês

10.1208/aapsj070355

1550-7416

Jenny Y. Chien, Stuart Friedrich, Michael Heathman, Dinesh P. de Alwis, Vikram Sinha,

Pharmaceutical studies and practices

Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation (M&S) are well-recognized powerful tools that enable effective implementation of the learn-and-confirm paradigm in drug development. The impact of PK/PD M&S on decision making and drug development risk management is dependent on the question being asked and on the availability and quality of data accessible at a particular stage of drug development. For instance, M&S methodologies can be used to capture uncertainty and use the expected variability in PK/PD data generated in preclinical species for projection of the plausible range of clinical dose; clinical trial simulation can be used to forecast the probability of achieving a target response in patients based on information obtained in early phases of development. Framing the right question and capturing the key assumptions are critical components of the “learn-and-confirm” paradigm in the drug development process and are essential to delivering high-value PK/PD M&S results. Selected works of PK/PD modeling and simulation from preclinical to phase III are presented as case examples in this article.